MeiraGTx Holdings plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MeiraGTx Holdings plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.39M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $33.28M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $14.02M | Mar 13, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2022 | $15.92M | Mar 14, 2023 |
| FY2021 | Dec 31, 2021 | $37.70M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $15.56M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $13.29M | Mar 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($114.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($147.79M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($84.03M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($129.62M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($79.56M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($57.99M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($54.75M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($82.87M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($31.04M) | Mar 26, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.97M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($164.21M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($137.06M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($116.36M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($72.76M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($62.55M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($58.27M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($78.10M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($31.68M) | Mar 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.62M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $119.48M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $103.79M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $85.73M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $66.69M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $33.91M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $24.88M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $33.62M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $22.36M | Mar 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.36M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($104.50M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($105.37M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($73.10M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($10.53M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($63.97M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $20.04M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($58.89M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($18.06M) | Mar 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.96M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $20.17M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $44.96M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $46.35M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $20.92M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $8.98M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $11.26M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $10.54M | Mar 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $244.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $269.75M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $326.74M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $318.24M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $320.16M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $363.70M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $323.89M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $96.89M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $25.85M | Mar 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.22M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $201.92M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $188.57M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $200.50M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $134.76M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $125.14M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $133.09M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $15.84M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $21.88M | Mar 26, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.79M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $67.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $138.18M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $117.74M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $185.40M | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | $238.56M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $190.80M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $81.06M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | ($47.37M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($17.14M) | Mar 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($816.22M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($702.02M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($554.23M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($470.20M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | ($340.59M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($261.03M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($203.04M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($148.29M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($65.42M) | Mar 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.93M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $103.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $129.57M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $115.52M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $137.70M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $209.52M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $227.23M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $68.08M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $8.55M | Mar 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | (1) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | (1) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.12M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 78.40M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 63.60M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 48.48M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | 44.55M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 44.19M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 36.79M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 27.39M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 8.71M | Mar 26, 2019 |